Table 11. Aripiprazole on QT interval in children and adolescents with mental disorders.

Outcome	Risk with intervention per 1,000	Risk with comparator per 1,000	Relative measure of association	Number of participants (studies)	Quality (GRADE)	Comments†
Aripiprazole versus placebo
Prolongation of QT interval	64	0	RR 7.58 (0.40, 143.03)	98 (1 RCT) (37,88)	Very low	No difference
Corrected QT (QTc) changes	NR	NR	MD −2.74 (−4.71, −0.77); SMD −0.13 (−0.22, −0.03)	1,776 (4 RCTs and 10 non-RCTs) (35,60-62,88)	Low	Favors aripiprazole
Electrocardiogram QT prolonged at the end of the study	62	35	RR 1.75 (0.17, 18.28)	60 (1 RCT) (95)	Very low	No difference
Aripiprazole, high dose 30 mg/d versus low dose 10 mg/d
Prolongation of QT interval	20	10	RR 1.98 (0.18, 21.48)	197 (1 RCT) (37,93)	Very low	No difference
Aripiprazole versus risperidone
Prolongation of QT interval	0	0	RR undetermined	60 (1CT) (36,37)	Very low	No difference
QT dispersion (QTd)	NR	NR	MD 1.60 (−1.66, 4.86); SMD 0.25 (−0.26, 0.76)	60 (1CT) (36,37)	Very low	No difference
Aripiprazole versus pimozide
Prolongation of QT interval	0	40	RR 0.33 (0.01, 7.81)	50 (1CT) (37,87)	Very low	No difference

^†, we concluded that there is no difference in outcomes between active and control interventions based on P value>0.05 and inability to reject null hypotheses but without post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in (); GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported.